[HTML][HTML] Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer
LS Otten, B Piet, MM van den Heuvel… - European …, 2022 - Eur Respiratory Soc
Background The risk for thromboembolisms in nonsmall cell lung cancer (NSCLC) patients
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …
[HTML][HTML] The Saudi consensus for the management of cancer-associated thromboembolism: a modified Delphi-based study
M Alsheef, S Bazarbashi, A Warsi, F Alfraih… - TH Open, 2023 - thieme-connect.com
Background Cancer is a well-known risk factor of preventable thromboembolic disease. This
study aims to provide guidance on the prevention and management of cancer-associated …
study aims to provide guidance on the prevention and management of cancer-associated …
Anticoagulation prescribing patterns in intensive care unit patients admitted with prehospital direct oral anticoagulant therapy: a single academic center experience
Objective: To describe the current prescribing practices of direct oral anticoagulants
(DOACs) in intensive care unit (ICU) patients and the associated clinical outcomes …
(DOACs) in intensive care unit (ICU) patients and the associated clinical outcomes …
[HTML][HTML] In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
Z Wang, Y Li, X He, Y Fu, Y Li, X Zhou… - Frontiers in …, 2023 - frontiersin.org
Background: Almonertinib, a third-generation epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for non-small cell …
kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for non-small cell …
[HTML][HTML] Effectiveness and safety of rivaroxaban in patients with venous thromboembolism and active cancer: A subanalysis of the J'xactly study
S Hisatake, T Ikeda, I Fukuda, M Nakamura… - Journal of …, 2023 - Elsevier
Background Data on the effectiveness and safety of rivaroxaban for the treatment of patients
with venous thromboembolism (VTE) and active cancer are limited in the Japanese real …
with venous thromboembolism (VTE) and active cancer are limited in the Japanese real …
Perioperační poruchy hemostázy
L Havlůj - 2022 - dspace.cuni.cz
SOUHRN Úvod: Hemostáza je součást homeostázy, její efektivita je založena na funkčnosti
systémů zástavy krvácení (primární hemostáza, primární a přídatné děje aktivace) a …
systémů zástavy krvácení (primární hemostáza, primární a přídatné děje aktivace) a …
[HTML][HTML] Роль антикоагулянтов в лечении и профилактике рецидивов венозных тромбоэмболических осложнений у пациентов со злокачественными …
ВЮ Мареев, ЮВ Мареев - Кардиология, 2022 - lib.ossn.ru
Аннотация Актуальность Венозные тромбоэмболические осложнения (ВТЭО) являются
основной неонкологической причиной смертности пациентов со злокачественными …
основной неонкологической причиной смертности пациентов со злокачественными …
[引用][C] Advancing management of pulmonary thromboembolic disease: from acute pulmonary embolism to pulmonary hypertension
C Samaranayake - 2023 - espace.library.uq.edu.au
Background and Aims Pulmonary thromboembolic disease encompasses a wide range of
clinical presentations during several stages of disease evolution from acute pulmonary …
clinical presentations during several stages of disease evolution from acute pulmonary …